GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.
300 patients around the world
Available in Argentina, United States, Spain
Hoffmann-La Roche
9Research sites
300Patients around the world
This study is for people with
Rare diseases
Huntington's chorea
Requirements for the patient
To 50 Years
All Gender
Medical requirements
Sites
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires